Objective To conduct a systematic review of studies reporting on the validity of International
Classification of Diseases (ICD) codes for identifying stroke in administrative data. Methods …

Background and Purpose—This ARISTOPHANES study (Anticoagulants for Reduction in
Stroke: Observational Pooled Analysis on Health Outcomes and Experience of Patients) …

Background Patients with atrial fibrillation who receive dialysis are at a high risk of ischemic
stroke. The role of warfarin in mitigating this risk in patients with atrial fibrillation who receive …

Background The introduction of non–vitamin K antagonist oral anticoagulants has been a
major advance for stroke prevention in atrial fibrillation; however, outcomes achieved in …

Importance Understanding the temporal association between atrial fibrillation (AF) and
ischemic stroke informs our understanding of the AF-stroke mechanism and treatment of …

The ARISTOTLE trial showed a risk reduction of stroke/systemic embolism (SE) and major
bleeding in non-valvular atrial fibrillation (NVAF) patients treated with apixaban compared to …

Results Compared with no anticoagulation, apixaban was not associated with lower
incidence of the primary outcome: hazard ratio, 1.24; 95% confidence interval, 0.69 to 2.23; …

Background Stroke patients have a high risk for recurrence, which is positively correlated
with the number of risk factors. The assessment of risk factors is essential in both stroke …

Background: The benefit-risk profile of direct oral anticoagulants (DOACs) compared with
warfarin, and between DOACs in patients with atrial fibrillation (AF) and chronic liver disease …

Objectives: The aim of this study was to assess temporal trends in the incidence of ischemic
stroke among patients undergoing percutaneous coronary intervention (PCI), predictors of …